608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors

類似資料

• Acute Interstitial Nephritis Triggered by a Novel Anti-CD25 Antibody-Drug Conjugate, Camidanlumab Tesirine
  著者:: Nicholas L. Li, 等
  出版事項: (2022-03-01)
• S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
  著者:: C. Carlo-Stella, 等
  出版事項: (2022-06-01)
• In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
  著者:: Paolo F. Caimi, 等
  出版事項: (2024-02-01)
• Vesiculobullous eruption with loncastuximab tesirine in a patient with relapsed follicular lymphoma
  著者:: Riyad N.H. Seervai, MD, PhD, 等
  出版事項: (2024-11-01)
• Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer
  著者:: Jonathan W. Goldman, 等
  出版事項: (2021-03-01)